Bryan Garnier

Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.

Mahaut Arnaud ... (+3)
  • Mahaut Arnaud
  • Paul de Froment
  • Thomas Mordelle

Ceres Power: Bosch exits strategic partnership

Ceres Power announced yesterday that its partner and major shareholder Bosch intends to end its partnership after a broad revision of its strategic focus and a thorough realignment regarding fuel cell technologies. As a consequence, Bosch is planning to (i) discontinue its operations and investment

Clement Genelot
  • Clement Genelot

Delivery Hero: Southeast Asia remains an issue

The recent Momentum Works' annual Asian update showed a continuous market share loss across Southeast Asia for Delivery Hero, reviving debate about this underperforming and loss-making unit. We continue to believe that a sale at any price or even a pure exit would eventually be positive for Deliver

Antoine Lebourgeois
  • Antoine Lebourgeois

Schneider: strong Q4 beat, FY25 guidance above consensus on growth and...

Schneider exceeded Q4 revenue expectations, posting 12.5% organic growth vs css at +7.9%, driven by a broad-based regional outperformance, EM strength and softer-than-expected IA weakness. H2 2024 adj. EBITA margin landed 40bps above css at 18.5%, bringing FY24 to 18.6%, 30bps ahead of the upper-en

Oscar Haffen Lamm
  • Oscar Haffen Lamm

Cinclus Pharma: US phase 3 trial to start in Q3'25

Cinclus Pharma reported its Q4 results with a cash position at SEK566.7mm and an EBIT at SEK(56.89m). With the current cash position and operational cash burn, we forecast a runway into H1 2027 — i.e. beyond the next value inflection point of the phase 3 readout in Q3 2026. On the operational side,

Cedric Rossi
  • Cedric Rossi

BIC: A pivotal year 2025

During the call, management stated that BIC was well-positioned to tackle a crucial FY25, which marks the final year of the group's Horizon Plan and the forthcoming announcement of CEO Gonzalve Bich's successor. Although BIC is traditionally conservative at this stage of the year, this level of cau

Gregory Ramirez
  • Gregory Ramirez

LECTRA BUY | EUR45 Good resistance Chinese lockdowns; strong orde...

º Q2 results were slightly below expectations, but remained decent despite lockdowns in China New system orders hold up well thanks to automotive Company guidance for 2022 has been tightened toward its mid-point

Thibault Morel
  • Thibault Morel

HMS NETWORKS: HMS Networks 2Q22 results above expectations | CONVICTIO...

HMS NETWORKS - CONVICTION BUY | SEK500 HMS Networks 2Q22 results above expectations 2Q22 sales and new orders above expectations Positive surprise on 2Q22 profitability

Cedric Rossi
  • Cedric Rossi

HUGO BOSS: Successful execution and healthy geo mix lead to raised FY2...

HUGO BOSS - NEUTRAL | EUR68 vs. EUR64 Successful execution and healthy geo mix lead to raised FY22 guidance Strong sales and EBIT beat in Q2 driven by execution… … and low exposure to China’s lockdowns FY22 sales and EBIT guidance revised upwards and we increase our FY22-23 estimates by 7%

Clement Genelot
  • Clement Genelot

ROCHE BOBOIS: Q4 topping expectations with good H1 2022 prospects

ROCHE BOBOIS: Q4 topping expectations with good H1 2022 prospects

Victor Floc’h
  • Victor Floc’h

ONCODESIGN (CORPORATE, TP EUR15) | R&D collaboration signed with TiumB...

ONCODESIGN (CORPORATE, TP EUR15) | R&D collaboration signed with TiumBio in fibrosis

ResearchPool Subscriptions

Get the most out of your insights

Get in touch